Pherecydes Pharma SA
Developing bacterial phages as anti-infectives
This article was originally published in Start Up
Scientists have long realized that certain viruses can destroy bacteria. Classified as bacteriophages, these viruses attach to specific receptors on the surface of bacteria and inject their own genetic material. Some so-called lytic phages kill their hosts right away and their progeny replicate as soon as the bacteria are lysed, or ruptured. Pherecydes Pharma SA, a start-up based in Romainville, France, is working to identify and modify large numbers of lytic phages, with the goal of creating therapies effective against antibiotic-resistant nosocomial infections.
You may also be interested in...
Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.